| Literature DB >> 35204218 |
Hsin-Yi Hung1, Kun-Ching Cheng2, Ping-Chung Kuo1, I-Tsen Chen3, Yue-Chiun Li1, Tsong-Long Hwang4,5,6, Sio-Hong Lam1, Tian-Shung Wu1.
Abstract
Seven new anthraquinones with rare 2-isopropyldihydrofuran (1-3) and 2,2-dimethylpyrano (4-7) moieties together with thirty-four known compounds were isolated from the extracts of whole Hedyotis diffusa plants. Their structures were elucidated and established by various spectroscopic and spectrometric analytical methods. Among these isolates, selected compounds were examined for their anti-inflammatory activity. The results showed that rare substituted anthraquinones displayed potent inhibitory activity with IC50 values ranging from 0.15 ± 0.01 to 5.52 ± 1.59 µM on the N-formyl-methionyl-leucyl-phenylalanine/cytochalasin B (fMLP/CB)-induced superoxide anion generation and elastase release cellular models. Meanwhile, the proposed drug target of the active anthraquinone was studied by computer modeling. The binding affinity between the anti-inflammatory anthraquinone and elastase was evaluated by molecular docking. These results provided the scientific insight into the medicinal values of Hedyotis diffusa and vision of development as lead compounds.Entities:
Keywords: Hedyotis diffusa; anthraquinone; elastase release; human neutrophils; superoxide anion
Year: 2022 PMID: 35204218 PMCID: PMC8868389 DOI: 10.3390/antiox11020335
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Scheme 1The extraction and isolation flow chart of H. diffusa.
The 1H NMR spectral data of compounds 1–7.
| 1 a | 2 b | 3 c | 4 a | 5 a | 6 d | 7 a | |
|---|---|---|---|---|---|---|---|
| Position | δH (ppm, multi, | ||||||
| 1 | 8.05 (s) | 7.60 (s) | 7.45 (s) | 8.07 (s) | 7.78 (s) | 7.47 (s) | 7.80 (s) |
| 5 | 8.22 (dd, | 8.08 (d, | 7.96 (brs) | 8.21 (m) | 8.10 (d, | 8.03 (d, | 7.64 (d, |
| 6 | 7.76 (m) | 7.65 (dd, | - | 7.73 (m) | 7.55 (dd, | 7.55 (brd, | 7.48 (d, |
| 7 | 7.76 (m) | - | 7.58 (brd, | 7.73 (m) | |||
| 8 | 8.28 (dd, | 7.98 (d, | 8.09 (d, | 8.21 (m) | 8.01 (d, | 7.94 (brs) | |
| 11 | 2.37 (s) | 2.51 (s) | 2.49 (s) | 2.32 (s) | 2.50 (s) | 2.43 (s) | 2.35 (s) |
| 1′ | 3.93 (dd, | 3.70 (d, | 5.77 (d, | 7.87 (d, | 7.93 (d, | 7.50 (s) | 7.92 (d, |
| 3.54 (dd, | |||||||
| 2′ | 5.39 (br t, | 4.89 (t, | 4.45 (d, | 5.94 (d, | 5.93 (d, | 5.94 (d, | |
| 4′ | 5.13 (s) α | 1.32 (s) | 1.33 (s) | 1.50 (s) | 1.53 (s) | 1.60 (s) | 1.54 (s) |
| 4.96 (s) ꞵ | |||||||
| 5′ | 1.80 (s) | 1.27 (s) | 1.29 (s) | 1.50 (s) | 1.53 (s) | 1.60 (s) | 1.54 (s) |
| OH−8 | 12.93 (s) | ||||||
1H NMR data (δ) were measured in a CDCl3 at 400 MHz; b acetone-d6 at 400 MHz; c methanol-d4 at 400 MHz; d methanol-d4 at 700 MHz.
The 13C NMR spectral data of compounds 1–7.
| 1 a | 2 b | 3 c | 4 a | 5 a | 6 d | 7 a | |
|---|---|---|---|---|---|---|---|
| Position | δC (ppm) | ||||||
| 1 | 130.7 | 114.4 | 117.0 | 130.2 | 113.7 | 110.7 | 113.4 |
| 2 | 125.8 | 145.7 | 144.4 | 132.5 | 149.0 | 151.5 | 149.0 |
| 3 | 164.3 | 153.5 | 155.3 | 157.1 | 144.8 | 148.8 | 145.2 |
| 4 | 128.1 | 131.4 | 130.8 | 120.7 | 121.8 | 132.0 | 122.1 |
| 4a | 128.6 | 128.9 | 129.9 | 126.6 | 121.8 | 120.1 | 122.1 |
| 5 | 126.7 | 126.6 | 126.5 | 127.0 | 127.2 | 127.9 | 118.9 |
| 6 | 133.5 | 134.3 | 144.4 | 133.6 | 134.6 | 136.0 | 136.9 |
| 7 | 133.9 | 144.6 | 134.0 | 133.4 | 144.3 | 146.0 | 133.7 |
| 8 | 127.1 | 126.7 | 126.5 | 126.5 | 126.8 | 128.3 | 160.4 |
| 8a | 133.8 | 133.6 | 132.0 | 127.2 | 132.6 | 134.8 | 114.8 |
| 9 | 182.3 | 181.7 | 183.4 | 182.9 | 182.9 | 185.2 | 188.2 |
| 9a | 127.2 | 123.4 | 120.0 | 132.9 | 129.7 | 134.0 | 129.2 |
| 10 | 184.5 | 182.6 | 183.3 | 185.7 | 184.6 | 184.2 | 184.1 |
| 10a | 127.2 | 131.8 | 133.5 | 134.9 | 132.7 | 133.5 | 132.8 |
| 11 | 15.8 | 20.8 | 20.4 | 16.5 | 21.8 | 21.9 | 16.0 |
| 1′ | 36.1 | 32.2 | 73.3 | 120.9 | 120.9 | 104.1 | 120.8 |
| 2′ | 87.7 | 92.0 | 96.2 | 133.8 | 133.5 | 170.0 | 133.7 |
| 3′ | 143.4 | 70.7 | 70.7 | 76.6 | 78.0 | 70.2 | 78.2 |
| 4′ | 112.4 | 24.7 | 23.6 | 28.0 | 27.9 | 29.2 | 28.0 |
| 5′ | 17.1 | 25.0 | 24.1 | 28.0 | 27.9 | 29.2 | 28.0 |
13C NMR data (δ) were measured in a CDCl3 at 100 MHz; b acetone-d6 at 100 MHz; c methanol-d4 at 100 MHz; d methanol-d4 at 175 MHz.
Figure 1Structures of anthraquinones 1–7 isolated from H. diffusa.
Figure 2Significant HMBC correlations of anthraquinones 1–7.
Effects of compounds on superoxide anion generation and elastase release in fMLP/CB-induced human neutrophils.
| Compounds | Superoxide Anion | Elastase Release | ||||
|---|---|---|---|---|---|---|
| IC50 (µg/mL) b | Inhibition% a | IC50 (µg/mL) b | Inhibition% a | |||
| 1 | 0.92 ± 0.22 | 97.92 ± 4.14 | *** | 0.71 ± 0.22 | 111.76 ± 2.97 | *** |
| 2 | 1.71 ± 0.15 | 103.01 ± 0.74 | *** | 2.40 ± 0.36 | 113.50 ± 5.04 | *** |
| 4 | 5.52 ± 1.59 | 61.53 ± 5.76 | *** | 3.25 ± 0.80 | 87.18 ± 2.92 | *** |
| 5 | 0.15 ± 0.01 | 108.59 ± 1.66 | *** | 0.20 ± 0.02 | 112.25 ± 4.99 | *** |
| 8 | 3.55 ± 0.48 | 99.28 ± 0.29 | *** | 3.88 ± 0.48 | 106.73 ± 3.10 | *** |
| 9 | 1.58 ± 0.42 | 80.72 ± 3.25 | *** | >10 | 45.45 ± 6.31 | ** |
| 11 | 5.29 ± 0.70 | 74.47 ± 2.80 | *** | >10 | 39.23 ± 6.61 | ** |
| 12 | >10 | 15.10 ± 5.84 | >10 | 31.44 ± 4.62 | ** | |
| 13 | >10 | 27.80 ± 4.16 | ** | >10 | 30.22 ± 4.05 | ** |
| 14 | >10 | 45.51 ± 6.33 | ** | >10 | 29.88 ± 4.62 | ** |
| 15 | 2.30 ± 0.58 | 97.18 ± 0.65 | *** | 5.12 ± 0.63 | 77.38 ± 2.92 | *** |
| 18 | >10 | 41.26 ± 6.15 | *** | >10 | 18.03 ± 6.74 | * |
| 19 | 4.96 ± 0.30 | 92.26 ± 2.51 | *** | 5.68 ± 1.73 | 67.08 ± 6.09 | *** |
| 20 | 3.66 ± 0.76 | 90.28 ± 6.56 | *** | 3.94 ± 0.77 | 91.40 ± 2.14 | *** |
| 21 | >10 | 43.09 ± 6.56 | ** | >10 | 13.88 ± 3.52 | * |
| 22 | >10 | 33.16 ± 5.19 | *** | >10 | 40.34 ± 5.97 | ** |
| 23 | >10 | 14.81 ± 6.93 | >10 | 6.63 ± 1.27 | ** | |
| 25 | >10 | 13.25 ± 5.20 | * | >10 | 8.29 ± 6.57 | |
| 26 | 1.46 ± 0.29 | 100.83 ± 0.83 | *** | 1.50 ± 0.25 | 113.90 ± 0.69 | *** |
| 27 | >10 | 2.57 ± 2.45 | >10 | −1.17 ± 2.02 | ||
| 28 | >10 | 13.05 ± 1.94 | ** | >10 | 9.17 ± 4.61 | |
| 29 + 30 | >10 | 5.56 ± 0.49 | *** | >10 | 21.55 ± 3.17 | ** |
| 31 + 32 | >10 | 8.07 ± 3.06 | >10 | 10.23 ± 2.80 | * | |
| 33 + 34 | >10 | 14.71 ± 2.44 | ** | >10 | −1.47 ± 2.84 | |
| 35 | 0.90 ± 0.23 | 80.63 ± 1.22 | *** | 5.15 ± 1.10 | 70.08 ± 2.36 | *** |
| 37 + 38 | 0.41 ± 0.05 | 105.16 ± 1.41 | *** | 1.81 ± 0.66 | 96.90 ± 5.09 | *** |
| 39 + 40 | >10 | 4.90 ± 4.15 | >10 | 2.68 ± 3.00 | ||
| 41 | >10 | 16.75 ± 4.02 | * | >10 | 21.21 ± 4.22 | ** |
| LY294002 | 0.75 ± 0.18 | 96.91 ± 5.99 | *** | 1.26 ± 0.48 | 88.81 ± 1.59 | *** |
a Percentage of inhibition (Inh.%) at 10 µg/mL concentration. Results are presented as mean ± S.E.M. (n = 3–4). * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the control value. b Concentration necessary for 50% inhibition (IC50).
Figure 3In silico modeling of (A) 1, (B) 5, and (C) GW475151 docking into the human neutrophil elastase receptor.
In silico computing binding energies of compounds 1, 5, and GW475151.
| Ligands | Binding Affinity (kcal/mol) |
|---|---|
|
| −6.9 |
|
| −7.2 |
| GW475151 | −5.8 |